4-Bromobenzo[b]thiophene CAS 5118-13-8 Purity >97.0% (GC) Isithombe Esifakiwe Se-Brexpiprazole Esimaphakathi Umkhiqizi

4-Bromobenzo[b]thiophene CAS 5118-13-8 Purity >97.0% (GC) Brexpiprazole Intermediate Manufacturer

Incazelo emfushane:

Igama Lekhemikhali: 4-Bromobenzo[b]thiophene

CAS: 5118-13-8

Ubumsulwa: >97.0% (GC)

Ukubukeka: Impushana Eqinile Ephuzi Ekhanyayo

I-Intermediate ye-Brexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

I-Ruifu Chemical Supply Brexpiprazole Intermediates
I-Brexpiprazole CAS 913611-97-9
I-7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Igama Lekhemikhali	4-Bromobenzo[b]thiophene
Omqondofana	4-Bromobenzothiophene;4-Bromo-Benzo[b]thiophene;4-Bromo-1-Benzothiophene
Inombolo ye-CAS	5118-13-8
Inombolo yeCAT	I-RF-PI1103
Isimo Sesitoko	Esitokweni, Umthamo 30MT/Ngonyaka
I-Molecular Formula	I-C8H5BrS
Isisindo samangqamuzana	213.09
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	Impushana Eqinile Ephuzi Ekhanyayo
Ukuhlanzeka / Indlela Yokuhlaziya	>97.0% (GC)
I-Infrared Spectrum	Ivumelana Nesakhiwo
I-NMR	Ivumelana Nesakhiwo
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	I-Intermediate ye-Brexpiprazole (CAS: 913611-97-9)

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

I-FAQ:

Isicelo:

I-4-Bromobenzo[b]thiophene (CAS: 5118-13-8) isetshenziswa njenge-synthetic intermediate ewusizo, futhi ithunyelwa kakhulu e-India, eNyakatho Melika, e-Korea, e-Japanese, naseYurophu.I-4-Bromobenzo[b]i-thiophene iyi-intermediate ye-Brexpiprazole (CAS: 913611-97-9).I-Brexpiprazole yagunyazwa yi-US Food and Drug Administration (FDA) ngoJulayi 10, 2015, ukuze zelashwe i-schizophrenia, futhi njengokwelashwa okuhlanganisayo kokudangala.I-Brexpiprazole yakhelwe ukuhlinzeka ngokusebenza okuthuthukisiwe kanye nokubekezelelana (isb, i-akathisia encane, ukungahlaliseki kanye/noma ukuqwasha) phezu kwemithi yokwengeza esunguliwe ye-depressive disorder (MDD).I-Brexpiprazole, ethengiswa ngaphansi kwegama lomkhiqizo i-Rexulti phakathi kwezinye, iyi-antipsychotic engavamile.I-Brexpiprazole iyi-dopamine D2 receptor partial agonist futhi ichazwe ngokuthi "i-serotonin-dopamine activity modulator" (SDAM).I-Brexpiprazole yathuthukiswa ngu-Otsuka kanye no-Lundbeck, futhi ithathwa njengelandela i-atypical antipsychotic aripiprazole (Abilify) yase-Otsuka ethengiswa kakhulu.